A randomized, double‐blind phase I/IIa study of intranasal glutathione in Parkinson's disease
暂无分享,去创建一个
Richard C. Lau | N. Polissar | A. Samii | M. Neradilek | L. Standish | J. Leverenz | Laurie K Mischley | Laurie K. Mischley
[1] M. Cotelli,et al. Cerebellar transcranial direct current stimulation in patients with ataxia: A double‐blind, randomized, sham‐controlled study , 2015, Movement disorders : official journal of the Movement Disorder Society.
[2] M. Ciriolo,et al. Glutathione: new roles in redox signaling for an old antioxidant , 2014, Front. Pharmacol..
[3] B. McLaughlin,et al. Redox modification of proteins as essential mediators of CNS autophagy and mitophagy , 2013, FEBS letters.
[4] M. Gregório,et al. Nullity of GSTT1/GSTM1 related to pesticides is associated with Parkinson's disease. , 2013, Arquivos de neuro-psiquiatria.
[5] Laurie K Mischley,et al. Safety survey of intranasal glutathione. , 2013, Journal of alternative and complementary medicine.
[6] T. Dall,et al. The current and projected economic burden of Parkinson's disease in the United States , 2013, Movement disorders : official journal of the Movement Disorder Society.
[7] M. Gregório,et al. Nullity of GSTT 1 / GSTM 1 related to pesticides is associated with Parkinson ’ s disease , 2013 .
[8] Laurie K Mischley,et al. Glutathione Deficiency in Parkinson ’ s Disease : Intranasal Administration as a Method of Augmentation , 2013 .
[9] A. Mollica,et al. Recent Advances in the Treatment of Neurodegenerative Diseases Based on GSH Delivery Systems , 2012, Oxidative medicine and cellular longevity.
[10] R. Hauser,et al. Determination of minimal clinically important change in early and advanced Parkinson's disease , 2011, Movement disorders : official journal of the Movement Disorder Society.
[11] Yu Tian Wang,et al. Depletion of GSH in glial cells induces neurotoxicity: relevance to aging and degenerative neurological diseases , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[12] K. Lyons,et al. Randomized, double‐blind, pilot evaluation of intravenous glutathione in Parkinson's disease , 2009, Movement disorders : official journal of the Movement Disorder Society.
[13] D. Dickson,et al. Incidental Lewy body disease and preclinical Parkinson disease. , 2008, Archives of neurology.
[14] H. Ren,et al. [A clinical study of N-acetylcysteine treatment in chronic hepatitis B patients]. , 2008, Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology.
[15] C. Marsden,et al. Alterations in the distribution of glutathione in the substantia nigra in Parkinson's disease , 2005, Journal of Neural Transmission.
[16] B. Lauterburg,et al. The systemic availability of oral glutathione , 2005, European Journal of Clinical Pharmacology.
[17] J. Piccirillo,et al. Psychometric and Clinimetric Validity of the 20-Item Sino-Nasal Outcome Test (Snot-20) , 2002, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.
[18] C. Shaw,et al. Neurodegenerative disorders in humans: the role of glutathione in oxidative stress-mediated neuronal death , 1997, Brain Research Reviews.
[19] G. Rosati,et al. Reduced intravenous glutathione in the treatment of early parkinson's disease , 1996, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[20] N. Kobrinsky,et al. Treatment of advanced malignancies with high-dose acetaminophen and N-acetylcysteine rescue. , 1996, Cancer investigation.
[21] C. Marsden,et al. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia , 1994, Annals of neurology.
[22] M. Brin,et al. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. , 1993, The New England journal of medicine.
[23] N. Guo,et al. Glutathione: New candidate neuropeptide in the central nervous system , 1992, Neuroscience.